8.4455892909851E-05 1.37944625085194E-05 -0.00068972312543109 -0.000548963303914671 -0.000520811339611228 -0.000182987767971504 0.000520811339611228 0.000239291696578071
Sign Up Today X
Thanks for submitting the form.
Stockreport

UBS Sees Continued Upside in Amgen (AMGN), Lifts Target to $400 [Yahoo! Finance]

Amgen Inc. (AMGN)  More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
On April 13, UBS lifted its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $400 from $390. It reiterated a Buy rating on the shares. The revision came as part of a broader Q1 preview across the pharmaceuticals and biotechnology group. On April 8, Truist also updated its view on the company. It boosted its price target to $325 from $319 and maintained a Hold rating, as part of a wider preview of Q1 earnings in biotech. The firm said that reactivity to regulatory and policy shifts across the sector has started to ease. It also pointed to a recent pickup in deal activity, which could build momentum through the rest of the year and into the mid-term period. For Amgen, Truist made a few specific adjustments. It increased its long-term penetration assumptions for Krystexxa, citing stronger patent protection that now extends into 2040. It also raised the probability of success for MariTide, reflecting greater confidence in its commercially viable profile in obesity. Amgen Inc. (NAS [Read more]
IMPACT SNAPSHOT EVENT TIME: AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AMGN alerts
from News Quantified
AMGN
NEWS
AMGN
Earnings
AMGN
Analyst Actions
AMGN
SEC Filings
Stockreport

UBS Sees Continued Upside in Amgen (AMGN), Lifts Target to $400 [Yahoo! Finance]

Amgen Inc.  (AMGN) 
More Company Research Source: Yahoo! Finance
Last amgen inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
On April 13, UBS lifted its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $400 from $390. It reiterated a Buy rating on the shares. The revision came as part of a broader Q1 preview across the pharmaceuticals and biotechnology group. On April 8, Truist also updated its view on the company. It boosted its price target to $325 from $319 and maintained a Hold rating, as part of a wider preview of Q1 earnings in biotech. The firm said that reactivity to regulatory and policy shifts across the sector has started to ease. It also pointed to a recent pickup in deal activity, which could build momentum through the rest of the year and into the mid-term period. For Amgen, Truist made a few specific adjustments. It increased its long-term penetration assumptions for Krystexxa, citing stronger patent protection that now extends into 2040. It also raised the probability of success for MariTide, reflecting greater confidence in its commercially viable profile in obesity. Amgen Inc. (NAS [Read more]
IMPACT SNAPSHOT
EVENT TIME:
AMGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS